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stipation. Comorbidities and drug utilization related to
constipation were also assessed.
RESULTS: 9,301 patients met all inclusion criteria. The
mean age was 39.74 years and 63.41% of the sample was
female. The most commonly observed comorbidities were
hypertension (16.3%), diabetes (7.5%), diverticulitis (7.4%)
and irritable colon (5.9%). Approximately 8% of the sam-
ple received medications thought to have constipating ef-
fects in the 6-month period prior to their constipation
diagnosis. Prescription laxative use was observed in ap-
proximately 3% of subjects after the constipation diagno-
sis. Average costs rose from $277 (SD  1717) 6 months
prior to the constipation diagnosis to $1031 (SD  4402)
during the month of the diagnosis. Similarly, average costs
decreased from $890 (SD  3852) in the month directly
following the index date to $479 (SD  3470) in the sixth
month following the index date.
CONCLUSION: Costs associated with the diagnosis and
treatment of constipation patients appear to be concen-
trated around the index visit. Early detection and resolu-
tion of constipation could result in significant cost savings
for managed care organizations.
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OBJECTIVES: To estimate the differential cost of using
non-steroidal anti-inflammatory drugs (NSAIDs) in a
Medicaid population. NSAID use is associated with ad-
verse gastrointestinal (GI) events such as GI distress, symp-
tomatic ulcer, and anemia, which vary in severity and may
require symptomatic treatment or hospitalization. The
economic burden of these events is represented by the dif-
ferential cost of treating NSAID-related toxicities.
METHODS: Treatment cost and adverse GI event rates
were compared for two cohorts (NSAID and non-NSAID
users) selected retrospectively from the South Carolina
Medicaid population. To be included in the analysis, all
subjects must have been at least 18 years old and continu-
ously eligible for 12 months following an index event in
1995. For NSAID users, the index event was at least two
NSAID prescriptions or a 60 day supply (n  21,278). For
non-NSAID users (comparator group), the index event
was at least one prescription during 1995 (n  152,072).
Average cost per subject by type of service (physician,
other ambulatory, inpatient hospital, outpatient hospital,
emergency department, prescription drugs) was compared
for the cohorts. Regression analysis was used to evaluate
the effect of NSAID use on treatment cost, controlling for
age, gender, prior exposure to NSAIDs, use of gastro-pro-
tective agents, and adverse GI events.
RESULTS: NSAID users had higher physician ($1885 vs.
$1488), other ambulatory ($5785 vs. $5060), inpatient
hospital ($5966 vs. $3326) and prescription drug ($1012
vs. $738) costs than the non-NSAID group. Regression
analysis showed that NSAID use was a significant explana-
tory variable (p  0.0001), as were age, gender, race, and
adverse GI events.
CONCLUSIONS: NSAID use is associated with higher av-
erage treatment costs and is a significant predictor of mod-
eled treatment costs after controlling for other effects. Sub-
stantial cost savings may be realized if NSAID-related GI
toxicities and adverse events can be managed or avoided.
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The Dyspepsia Project is a General Practitioners’ (GPs)
project, aiming to establish an epidemiological database in
order to describe and follow up dyspeptic patients in the
Ravenna area.
OBJECTIVE: To investigate the feasibility of a cost of ill-
ness study on the dyspeptic patient in terms of healthcare
resource use, and to produce an average cost per patient.
METHOD: Retrospective cost of illness analysis based on
records of 106 dyspeptic patients followed by 10 GPs.
This preliminary analysis has been performed in the per-
spective of Health System. Patients analyzed were enrolled
between September and December 1999 and followed up
at least for 6 months. Hospital admissions; GP, specialist
and emergency room visits; instrumental and laboratory
tests; drugs were analyzed; each cost variable was valued
in Italian Liras 1999 (1800 ITL  1 US$) using published
regional or national tariffs and marked prices for drugs.
Patients have been divided into Group A (37  35%) and
Group B (69  65%), according to whether they under-
went or not gastroscopy test.
RESULTS: The average cost per patient was ITL
1,121,654 in A Group and ITL 624,565 in B Group. Di-
rect costs accounted for 76.5% of the total value in A
Group and for 70.9% in B Group, while the remaining
23.5% in A Group and 29.1% in B Group was due to in-
direct costs (i.e., productivity losses). In Group A the ma-
jor cost driver was drugs (40.8%) (13.6% was the share of
antidyspeptic drugs) followed by tests (18.4%), visits
(15.6%) and emergency room visits (1.7%); in B Group
the major cost driver was drugs (38.6%) (10.1% was the
share of antidyspeptic drugs) followed by visits (19.5%),
tests (9.2%) and emergency room visits (3.6%).
CONCLUSIONS: Collection of cost data at General Prac-
titioner’s level is very effective as it allows a precise and ap-
propriate analysis.
